Arena Pharma (ARNA) Misses Q4 EPS by 28c

Arena Pharma (NASDAQ: ARNA) reported Q4 EPS of ($2.54), $0.28 worse than the analyst estimate of ($2.26). Revenue for the quarter came in at $54 thousand versus the consensus estimate of $660 thousand.

Cash, cash equivalents and marketable securities were $0.7 billion at December 31, 2021 as compared to $1.1 billion at December 31, 2020

For earnings history and earnings-related data on Arena Pharma (ARNA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c